Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection

1991 ◽  
Vol 127 (5) ◽  
pp. 740-741 ◽  
Author(s):  
D. M. Porteous
Author(s):  
Punit S. Ramrakha ◽  
Kevin P. Moore ◽  
Amir H. Sam

This chapter discusses dermatological emergencies, including cutaneous drug reactions, erythroderma, urticaria and angio-oedema, autoimmune bullous disease, eczema herpeticum, herpes zoster, generalized pustular psoriasis, and Stevens–Johnson syndrome and toxic epidermal necrolysis.


2020 ◽  
Vol 7 (09) ◽  
pp. 5044-5047
Author(s):  
Akpa MA ◽  
Akogu SPO ◽  
Abba MA

This is a case report of a 41 year old multipara with human immunodeficiency virus (HIV) infection with an interesting history. She was initially commenced on a regimen of antiretroviral which included nevirapine in her non pregnant state. A change of drugs to replace nevirapine with efavirenz was instituted when skin rash was noticed. Unfortunately, she was recommenced on nevirapine when she became pregnant at 15 weeks gestation and developed symptoms of Stevens Johnson syndrome necessitating admission and treatment following which she made a full recovery. The presentation of this case highlights the importance of pharmacovigilance and health education to patients about adverse drug reactions.


2020 ◽  
Vol 7 (4) ◽  
Author(s):  
Puteri Nabilah Maharani ◽  
Oki Suwarsa ◽  
Susantina Prodjosoewojo

Background: Adverse cutaneous drug reactions (ACDRs) are common problems in patients during the treatment of various diseases. The clinical feature varies from mild manifestation such as morbilliform, urticaria, and contact dermatitis, to severe manifestation such as Stevens - Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Patients infected with the human immunodeficiency virus (HIV) have an increased risk of developing ACDRs due to immune system disruption. This study aimed to describe the clinical features of ACDRs in HIV patients and the drugs that cause ACDRs. Method: This study was a retrospective study using secondary data from medical records of HIV patients with ACDRs who visited Teratai Clinic of Dr. Hasan Sadikin General Hospital Bandung from 2014 to 2018. Total sampling was applied and results were presented in percentage. Results: There were 94 HIV patients with ACDRs out of 557 HIV patients. Adverse cutaneous drug reactions are commonly found in males aged 20-39 years old. The clinical features found were morbilliform (85.6%), SJS (8.9%), urticaria (4.4%), and erythroderma (1.1%). The most common drugs causing ACDRs were Cotrimoxazole (30%), Efavirenz (28.9%), and Nevirapine (16.7%). Conclusion: The prevalence of ACDRs in HIV patients in this study is 16.9%. The most common clinical features are morbilli form and SJS with Cotrimoxazole, Efavirenz, and Nevirapine causing most of the ACDRs.


2016 ◽  
Vol 62 (5) ◽  
pp. 468-473 ◽  
Author(s):  
Anthony Wong ◽  
Andrey Augusto Malvestiti ◽  
Mariana de Figueiredo Silva Hafner

SUMMARY Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon, acute and potentially life-threatening adverse cutaneous drug reactions. These pathologies are considered a hypersensitivity reaction and can be triggered by drugs, infections and malignancies. The drugs most often involved are allopurinol, some antibiotics, including sulfonamides, anticonvulsants such as carbamazepine, and some non-steroid anti-inflammatory drugs (NSAIDs). Necrosis of keratinocytes is manifested clinically by epidermal detachment, leading to scalded skin appearance. The rash begins on the trunk with subsequent generalization, usually sparing the palmoplantar areas. Macular lesions become purplish, and epidermal detachment occurs, resulting in flaccid blisters that converge and break, resulting in extensive sloughing of necrotic skin. Nikolsky's sign is positive in perilesional skin. SJS and TEN are considered to be two ends of the spectrum of one disease, differing only by their extent of skin detachment. Management of patients with SJS or TEN requires three measures: removal of the offending drug, particularly drugs known to be high-risk; supportive measures and active interventions. Early diagnosis of the disease, recognition of the causal agent and the immediate withdrawal of the drug are the most important actions, as the course of the disease is often rapid and fatal.


Sign in / Sign up

Export Citation Format

Share Document